June 15, 2017 — In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST-elevation ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare costs ...
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) ...
May 26, 2017 — Statins are associated with improved heart structure and function, according to research presented at ...
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal ...
May 12, 2017 — More than one-third of patients undergoing transcatheter aortic valve replacement (TAVR) were observed to ...
May 12, 2017 – A new study found that dementia rates increase with delays in starting anticoagulation treatment for atri ...
Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on ...
May 5, 2017 — A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing ...
May 16, 2017 — Here is a list of the late-breaking clinical trials presented at the Heart Rhythm Society (HRS) 2017 ...
April 3, 2017 — There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes ...
March 29, 2017 — Uninterrupted treatment with dabigatran (Pradaxa), a non-vitamin K, novel antagonist oral anticoagulant ...
March 29, 2017 — Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good ...
March 29, 2017 — In patients with a complete, persistent arterial blockage, medication alone was found to be equal to pe ...
March 28, 2017 — When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not ...